Cargando…

Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma

Isocitrate dehydrogenase (IDH) mutations are a prognostic factor in diffuse glioma. However, the mechanism by which these mutations improve prognosis are not clear. In a subset of IDH-mutant glioma, remodeling of the methylome results in the glioma-CpG island methylator phenotype (G-CIMP) and transc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukunaga, Takanori, Fujita, Yuki, Kishima, Haruhiko, Yamashita, Toshihide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214530/ https://www.ncbi.nlm.nih.gov/pubmed/30388142 http://dx.doi.org/10.1371/journal.pone.0206552

Ejemplares similares

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
por: Ferreyra Vega, Sandra, et al.
Publicado: (2023)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
por: Huang, L. Eric
Publicado: (2022)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?
por: Marosi, Christine
Publicado: (2018)

Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas
por: Wang, Xinyu, et al.
Publicado: (2023)

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
por: Sanada, Takahiro, et al.
Publicado: (2021)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
por: Viswanath, Pavithra, et al.
Publicado: (2016)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
por: Flanagan, Simon, et al.
Publicado: (2012)

NI-13 THE RATIO OF T1-WEIGHTED TO T2-WEIGHTED SIGNAL INTENSITY AND IDH MUTATION IN GLIOMA
por: Sanada, Takahiro, et al.
Publicado: (2022)

IGFBP2 expression predicts IDH-mutant glioma patient survival
por: Huang, Lin Eric, et al.
Publicado: (2016)

Mutant IDH1 regulates the tumor-associated immune system in gliomas
por: Amankulor, Nduka M., et al.
Publicado: (2017)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
por: Richardson, Leland G., et al.
Publicado: (2020)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lucngtrkqurvk5lrho1961ubhb